IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life ...
GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. | GSK once dreamed of ...
The intervention involves two experimental doses of leronlimab, a monoclonal antibody targeting CCR5, combined with Trifluridine + Tipiracil (TAS-102) and Bevacizumab, aiming to enhance treatment ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study. | Zenas Biopharma’s lead autoimmune drug ...
AbbVie is conducting a Phase 2 study titled A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan ...
Vietnam Investment Review on MSN
Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial
Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) announced that its first-in-class idiopathic pulmonary ...
Lynch Syndrome (LS) is a common hereditary condition that greatly increases lifetime risk of colorectal, endometrial, urothelial and other cancersNOUS-209 is an off-the-shelf immunotherapy designed to ...
Neurocrine Biosciences (($NBIX)) announced an update on their ongoing clinical study. Neurocrine Biosciences has recently completed a Phase 2 ...
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically ...
The published manuscript detailed the safety and efficacy results of INT230-6, Intensity’s intratumoral therapy for treating metastatic or refractory cancers. The data showed a 75% disease control ...
The drug, which is an NLRP3 inhibitor, also reduced other key cardiovascular risk biomarkers. Ventyx Biosciences plans to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback